Thursday, July 25, 2019

AASLD guidelines for treatment of chronic hepatitis B in pregnancy


Here is a quick summary.

All infants of HBsAg-positive women should receive HBV vaccination ± hepatitis B immunoglobulin.

Pregnant women who have hepatitis B virus DNA levels greater than 200,000 IU/mL at 24 to 28 weeks' gestation should be treated with antivirals to prevent vertical transmission during delivery.

Antivirals studied in pregnant women: Lamivudine, telbivudine, and tenofovir.

Antiviral therapy was discontinued at birth to 3 months postpartum. With discontinuation of treatment, women should be monitored for ALT flares every 3 months for 6 months.

Breastfeeding is not contraindicated - antivirals are minimally excreted in breast milk.

C-section is not indicated - insufficient data to support benefit.




  1. I think you need to rethink regarding title of this blog


This is express yourself space. Where you type create something beautiful! <3
Wondering what do I write? Well...
Tell us something you know better. You are a brilliant mind. Yes, you are! ^__^
Ask about something you don't understand @_@?
Compliment... Say something nice! =D
Be a good critic and correct us if something went wrong :|
Go ahead. Comment all you like here! (:

PS: We have moderated comments to reduce spam. ALL comments that are not spam will be published on the website.